Search cutoffs
Search companies, layoffs, filings, signals, and visa data
Search companies, layoffs, filings, signals, and visa data
Search companies, layoffs, filings, signals, and visa data
Search companies, layoffs, filings, signals, and visa data
Search companies, layoffs, filings, signals, and visa data
Current report (Form 8-K) · Jun 3, 2026 · Multiple disclosures including asset impairment and material agreement
| Item 1.01 | Entered a material definitive agreement |
| Item 1.02 | Terminated a material definitive agreement |
| Item 2.06 | Recorded a material impairment |
| Item 7.01 | Regulation FD disclosure (investor press release or presentation) |
| Item 8.01 | Other events the company considers material |
| Item 9.01 | Financial statements and exhibits |
ADC Therapeutics SA filed this to report entering into or terminating a material contract that could affect operations, partnerships, or future hiring.
1 ADC Therapeutics Announces Results From LOTIS-5 Phase 3 Confirmatory Clinical Trial of ZYNLONTA ® in Combination with Rituximab in Relapsed or Refractory Diffuse Large B-Cell Lymphoma Company to host conference call today at 4:30 p. EDT LAUSANNE, Switzerland, June 3, 2026 – ADC Therapeutics SA (NYSE: ADCT) today announced topline data from its Phase 3 LOTIS-5 confirmatory trial evaluating ZYNLONTA ® (loncastuximab tesirine-lpyl) in combination with rituximab in patients with relapsed or refractory d…
This filing reports Item 1.01 (entered a material definitive agreement); Item 1.02 (terminated a material definitive agreement); Item 2.06 (recorded a material impairment); Item 8.01 (other events the company considers material). These item codes often precede or accompany restructuring, leadership changes, or deals that can shift headcount.
ADC Therapeutics SA reported material events that can affect workforce planning. cutoffs surfaces the filing alongside WARN layoffs, H-1B activity, and company signals.
